ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail investors. See more on IBRX stock here.

We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this article, we are going to take a ...

We recently compiled a list of the These 10 Firms Dominated Last Week’s Rally. In this article, we are going to take a look ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. D. Boral Capital ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...

ImmunityBio also said it will submit a regulatory filing for an alternative source of Bacillus Calmette-Guerin, a drug which treats bladder cancer. The company expects to produce large quantities of ...

ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low ...

ImmunityBio is at the forefront of developing innovative immunotherapies and cell therapies. The company has a vertically integrated approach, allowing it to oversee every step of development, from ...

BTIG analyst Justin Zelin initiated coverage of ImmunityBio (IBRX) with a Buy rating and $6 price target Lead product Anktiva is approved in ...

In this article, we are going to take a look at where Immunitybio, Inc. (NASDAQ:IBRX) stands against other firms that took a hit on Friday. Wall Street’s main indices all finished in the green ...